Introduction
============

Over the past decade, utilization of bilateral mastectomy for unilateral breast cancer has increased.[@b1-cmar-9-649]--[@b3-cmar-9-649] This may be attributed to a multitude of factors including fear of developing another breast cancer, the use of highly sensitive diagnostic modalities such as magnetic resonance imaging, improved diagnosis of hereditary breast cancer as in patients with *BRCA* mutations, and improved access to breast reconstruction.[@b1-cmar-9-649],[@b2-cmar-9-649],[@b4-cmar-9-649]--[@b12-cmar-9-649] However, bilateral mastectomy is an extensive surgical procedure which often results in longer inpatient hospital stays, higher transfusion rates, and increased reoperation rates.[@b13-cmar-9-649]--[@b15-cmar-9-649] The risks traditionally associated with unilateral breast reconstruction may be compounded in patients undergoing bilateral reconstruction.[@b13-cmar-9-649],[@b15-cmar-9-649] Additionally, the costs associated with lengthened operative time and inpatient hospital stays are increasingly monitored and must be considered when caring for breast cancer patients.

Randomized controlled trials comparing survival in patients undergoing bilateral mastectomy with traditional surgical options such as breast conservation therapy (BCT) or unilateral mastectomy have not been performed. Using the Surveillance, Epidemiology, and End Results (SEER) database, several studies have found that patients undergoing bilateral mastectomy have a significant reduction in the adjusted hazard of breast cancer death when compared with those undergoing unilateral mastectomy.[@b3-cmar-9-649],[@b16-cmar-9-649],[@b17-cmar-9-649] However, limitations in follow-up duration and in statistical design have led to questions surrounding interpretation of these findings.

In this study, we evaluated breast cancer death using the SEER database with at least 10 years of censored follow-up by performing a matched patient cohort directly comparing bilateral mastectomy with unilateral mastectomy for unilateral breast cancer.

Methods
=======

Data source
-----------

Case-level deidentified data from 1998 to 2002 were extracted from the SEER cancer database (November 2014 submission) with follow-up and survival cut-off until December 31, 2012. Data accessed from the SEER are publicly available free of charge. This allowed for a minimum 10-year survival analysis. The SEER database is a national effort that collects patient-level data for all index malignant tumors in 18 cancer registries across the USA and captures roughly 28% of the nation's population. This database is regarded as nationally representative and contains detailed demographic, socioeconomic, oncologic, and treatment information. To ensure data accuracy, chart abstractors undergo extensive training. Malignant tumors are encoded by use of the ninth revision of the *International Classification of Diseases for Oncology*.

Inclusion/exclusion criteria
----------------------------

Data were extracted from the SEER database for all female patients with a unilateral, invasive ductal breast cancer (*International Classification of Diseases for Oncology* code 8500) who underwent unilateral or bilateral mastectomy (site-specific surgery codes -- unilateral: 41, 43, 44, 45, 46, 51, 53, 54, 55, 56; bilateral: 42, 47, 48, 49, 52, 57, 58, 59, 63, 75). Patients with unknown stage or histology code other than 8500 were excluded.

Matching methodology
--------------------

Patients were matched on three critical variables to account for tumor severity (stage), follow-up time (year of diagnosis), and age at diagnosis. Exact matching for stage and year of diagnosis were performed, and Mahalanobis-metric matching method was used for age of diagnosis. The result was a 4-to-1 matched cohort sample.

Statistical analysis
--------------------

Pre-matched and post-matched absolute standard differences of patient characteristics were compared to assess covariance balance. Additionally, pre- and post-matched groups were compared using chi-square tests for categorical factors and Wilcoxon tests for continuous factors. Associations of breast cancer--specific death with unilateral versus bilateral mastectomy were assessed with adjusted and unadjusted Cox proportional hazards models. Breast cancer-specific death was defined as death caused by breast cancer. Stage, age at diagnosis, and year of diagnosis were included to account for the cluster effect in the matched data.

Results
=======

Patient characteristics (pre-matching)
--------------------------------------

A total of 41,510 patients were diagnosed with unilateral, invasive breast cancer, stage I--IV, from 1998 through 2002. A majority of patients underwent unilateral mastectomy (n=38,596; 93.0%). There were statistically significant differences between patients who underwent unilateral and bilateral mastectomy with respect to year of diagnosis, tumor stage, age at diagnosis, race, nodal involvement, tumor size, tumor grade, and breast reconstruction status (*p*\<0.005 for each covariate; [Table 1](#t1-cmar-9-649){ref-type="table"}).

Patient characteristics (post-matching)
---------------------------------------

Patient matching was performed using year of diagnosis, tumor stage, and age at diagnosis ([Table 2](#t2-cmar-9-649){ref-type="table"}). Matching on year of diagnosis allowed for well-balanced follow-up time. After matching, the original 2,815 (20%) patients who underwent bilateral mastectomy were included with 11,260 (80%) patients who underwent unilateral mastectomy. In the post-match analysis, patient characteristics including nodal involvement, tumor size, tumor grade, and reconstruction status remained significantly different ([Table 2](#t2-cmar-9-649){ref-type="table"}). However, overall imbalance between the two cohorts improved substantially with absolute standardized differences (%) below 0.4% for all factors.

Bilateral mastectomy is not independently associated with adjusted breast cancer--specific death
------------------------------------------------------------------------------------------------

Kaplan--Meier survival analysis showed that patients treated with bilateral mastectomy had improved "unadjusted" breast cancer--specific survival when compared with matched patients treated with unilateral mastectomy ([Figure 1](#f1-cmar-9-649){ref-type="fig"}). "Unadjusted" Cox proportional hazard analysis confirmed that patients who underwent bilateral mastectomy had reduced breast-cancer specific death when compared with matched patients who underwent unilateral mastectomy (hazard ratio \[HR\] 0.86, *p*\<0.003).

To adjust for additional demographic and oncologic variables including patient race, estrogen receptor/progesterone receptor (ER/PR) status, radiation therapy, and reconstruction status, adjusted Cox proportional hazard regression analysis comparing the two matched groups was performed. With this model, the estimated death among patients who underwent bilateral mastectomy was not reduced (HR 0.92, 95% confidence interval \[95% CI\]: (0.83, 1.02), *p*=0.11; [Table 3](#t3-cmar-9-649){ref-type="table"}).

Discussion
==========

In this population-based study, we utilized the National Cancer Institute (NCI) SEER database to compare cause-specific death in patients who underwent bilateral mastectomy and unilateral mastectomy for unilateral breast cancer. Using a 4-to-1 matched cohort of patients diagnosed with unilateral breast cancer from 1998 to 2002, we found no statistically significant improvement in the hazard of breast cancer death among patients who underwent bilateral mastectomy.

In our analysis, we matched the unilateral and bilateral mastectomy cohorts based on three key variables -- tumor stage, patient age, and year of diagnosis. These variables were selected so that patients would be matched on variables which can influence decision-making (tumor stage), length of follow-up (year of diagnosis), and overall health condition (age). Further adjustments were included in an effort to account for covariate imbalance between the groups or because these variables such as race or reconstruction status have been previously shown to clinically associate with survival.[@b18-cmar-9-649],[@b19-cmar-9-649] Although in aggregate there were over 13 times as many patients who underwent unilateral mastectomy as those who underwent bilateral mastectomy, matching was performed for each individual patient with exact matching for stage and year of diagnosis. Therefore, the largest consistent representative match that could be obtained was a 4-to-1 match. Our table indicates that post-matched samples achieved good balance between groups.

Using the SEER database to study patients diagnosed with unilateral breast cancer between 1998 and 2003 with censored follow-up through 2005, Bedrosian et al found a statistically significant reduction in the adjusted hazard of breast cancer death in patients who underwent bilateral mastectomy when compared with patients who underwent unilateral mastectomy (0.84 vs 1.0, 95% CI \[0.76, 0.92\]).[@b16-cmar-9-649] These findings contrast with our analysis of the national SEER database using matched cohorts, which did not show a statistically significant relative decrease in risk of cause-specific death. In our analysis, patients were restricted to a single histologic code, ductal carcinoma (8500), to reduce heterogeneity among tumors. Additionally, their analysis did not adjust for reconstruction status, which has also been shown to strongly associate with breast cancer death.[@b18-cmar-9-649],[@b20-cmar-9-649] Furthermore, for our model, we selected patients diagnosed during a limited time period from 1998 through 2002. Although this limits the number of patients in our cohorts, it allowed us to increase the length of follow-up, a critical issue because breast cancer surveillance is a life-long process. We chose this specific interval of years to allow for uniformity in staging according to the American Joint Committee on Cancer, 3rd edition, and to also minimize the impact of temporal changes in technology or chemotherapy which may affect outcomes.[@b21-cmar-9-649]

Two more recent studies have compared breast cancer death after bilateral mastectomy, unilateral mastectomy, or BCT.[@b3-cmar-9-649],[@b17-cmar-9-649] Kurian et al used the California Cancer Registry, a component registry of SEER, to show that patients who undergo bilateral mastectomy have similar hazard of breast cancer death when compared with patients who undergo BCT, but interestingly they found a significantly reduced hazard of breast cancer death when compared with patients undergoing unilateral mastectomy.[@b17-cmar-9-649] Wong et al performed a similar analysis using the SEER database with similar results.[@b3-cmar-9-649] However, the interpretation of these results is unclear because a three-way analysis was performed with bilateral mastectomy, unilateral mastectomy, and BCT. The inclusion of BCT in a comparison with unilateral and bilateral mastectomy leads to lack of distributional overlap for variables such as radiation therapy. Radiation is considered a standard part of the treatment regimen for BCT, but not for patients who receive mastectomy. By performing an analysis excluding BCT, we were able to directly compare unilateral and bilateral mastectomy, in which the general indications for radiation therapy remained similar. Direct comparison of unilateral and bilateral mastectomy suggests that breast cancer--specific death after bilateral mastectomy is not significantly reduced when compared with unilateral mastectomy.

Limitations
===========

Our study has several limitations associated with a large database study. First, we were unable to account for variables that were not reported by the SEER database, including chemotherapy use and lymphovascular invasion.[@b22-cmar-9-649]--[@b24-cmar-9-649] Nevertheless, patients matched for the stage of disease would be expected to have the same indications for chemotherapy regardless of whether they undergo bilateral or unilateral mastectomy. We were also unable to account for other risk factors such as *BRCA* status and family history.[@b8-cmar-9-649] Furthermore, data accuracy is limited to reporting in patient charts and subsequent data abstraction.[@b25-cmar-9-649] Finally, we were unable to directly address comorbidities among patients who underwent bilateral or unilateral mastectomy; however, our cohorts were matched based on age.

Conclusion
==========

Patients must feel comfortable with their choice of surgical therapy, from initial consultation to peri-operative and postoperative management and reconstruction. The decision to undergo bilateral mastectomy is likely multifactorial and strong associations have been shown with patient age, race, and even reconstruction status.[@b2-cmar-9-649] Patients may choose to undergo bilateral mastectomy due to anxiety and perceptions regarding risk of contralateral breast cancer.[@b11-cmar-9-649] In addition, patients may believe that bilateral mastectomy will improve reconstruction outcomes.[@b11-cmar-9-649] Recently, a survey study found that breast surgeons remain uncomfortable with bilateral mastectomy due to ambiguity with oncologic outcomes and highlighted a need for further research.[@b26-cmar-9-649] Although bilateral mastectomy may not offer patients a survival benefit, it may alleviate other patient concerns, and survival analysis may not provide a complete picture of the benefits of bilateral mastectomy. Nonetheless, given the risks associated with bilateral mastectomy and the costs associated with longer operative times and lengthier inpatient hospitalization, it is important to obtain objective outcome measures of bilateral mastectomy.[@b13-cmar-9-649]--[@b15-cmar-9-649] In the present analysis, we showed that among patients with unilateral breast cancer, patients treated with bilateral mastectomy do not have a statistically or clinically significant reduction in breast cancer--specific death when compared with patients treated with unilateral mastectomy.
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###### 

Pre-match patient characteristics

  Characteristics            N        Bilateral % (n)   Unilateral % (n)   Test statistic
  -------------------------- -------- ----------------- ------------------ ----------------------------------------
                                      N = 2,815         N = 38,695         
  **Year of diagnosis**      41,510                                        $\chi_{4}^{2} = 150.74$, *p* \< 0.001
  1998                                7 (204)           12 (4,808)         
  1999                                9 (261)           12 (4,686)         
  2000                                22 (630)          25 (9,753)         
  2001                                30 (834)          26 (9,975)         
  2002                                31 (886)          24 (9,473)         
  **Stage**                  41,510                                        $\chi_{3}^{2} = 104.39$, *p* \< 0.001
  I                                   43 (1197)         35 (13,386)        
  IIA                                 27 (752)          26 (10,119)        
  IIB                                 12 (330)          14 (5,566)         
  IIIA                                10 (293)          12 (4,782)         
  IIIB                                2 (67)            3 (1,273)          
  IIIC                                5 (132)           6 (2,400)          
  IIINOS                              0 (9)             1 (206)            
  IV                                  1 (35)            2 (959)            
  **Age at diagnosis (y)**   41,510   51 (43,59)        49 (59,72)         *F*~1.41509~ = 840.69, *p* \< 0.001
  **Race**                                                                 $\chi_{3}^{2} = 158.88$, *p* \< 0.001
  White                      41,510   90 (2,532)        80 (31,079)        
  Black                               5 (146)           10 (3,896)         
  Other                               5 (131)           9 (3,626)          
  Unknown                             0 (6)             0 (94)             
  **Node involvement**                                                     $\chi_{2}^{2} = 59.82$, *p* \< 0.001
  0 nodes                    41,510   56 (1,566)        50 (19,367)        
  1--3 nodes                          27 (771)          27 (10,389)        
  \>3 nodes                           17 (478)          23 (8,939)         
  **Tumor size (mm)**        40,607   10 (17,28)        13 (20,32)         *F*~1.40605~ =163.43, *p* \< 0.001
  **Tumor size**             41,510                                        $\chi_{3}^{2} = 134.53$, *p* \< 0.001
  0--20 mm                            53 (1,499)        43 (16,528)        
  21--40 mm                           32 (894)          36 (14,083)        
  41+ mm                              13 (358)          19 (7,245)         
  Unknown                             2 (64)            2 (839)            
  **Grade**                  41,510                                        $\chi_{4}^{2} = 15.11$, *p* = 0.004
  I                                   13 (375)          12 (4,522)         
  II                                  37 (1,037)        38 (14,755)        
  III                                 43 (1,211)        44 (17,158)        
  IV                                  3 (83)            2 (850)            
  Unknown                             4 (109)           4 (1,410)          
  **Reconstruction (yes)**   41,510   39 (1,104)        13 (5,052)         $\chi_{1}^{2} = 1422.03$, *p* \< 0.001
  **Receptor status**                                                      
  ER: positive               41,510   61 (1,722)        61 (23,515)        $\chi_{3}^{2} = 6.14$, *p* = 0.105
  ER: negative                        25 (696)          24 (9,096)         
  ER: borderline                      0 (6)             0 (89)             
  ER: unknown                         14 (391)          15 (5,995)         
  PR: positive                        53 (1,482)        50 (19,429)        $\chi_{3}^{2} = 13.61.$ *p* = 0.003
  PR: negative                        32 (907)          32 (12,404)        
  PR: borderline                      0 (11)            1 (217)            
  PR: unknown                         15 (415)          17 (6,645)         

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor.

###### 

Post-match patient characteristics

                             N        Bilateral % (n)   Unilateral % (n)   Test statistic
  -------------------------- -------- ----------------- ------------------ ---------------------------------------
                                      N = 2,815         N = 11,260         
  **Year of diagnosis**      14,075                                        $\chi_{4}^{2} = 0$, *p* = 1
  1998                                7 (204)           7 (816)            
  1999                                9 (261)           9 (1,044)          
  2000                                22 (630)          22 (2,520)         
  2001                                30 (834)          30 (3,336)         
  2002                                31 (886)          31 (3,544)         
  **Stage**                  14,075                                        $\chi_{4}^{2} = 0$, *p* = 1
  I                                   43 (1,197)        43 (4,788)         
  IIA                                 27 (752)          27 (3,008)         
  IIB                                 12 (330)          12 (1,320)         
  III                                 18 (501)          18 (2,004)         
  IV                                  1 (35)            1 (140)            
  **Age at diagnosis (y)**   14,075   43 (51,59)        43 (51,59)         *F*~1.14073~ = 0.16, *p* = 0.689
  **Race**                   14,075                                        $\chi_{3}^{2} = 133.86$, *p* \< 0.001
  White                               90 (2,532)        81 (9,112)         
  Black                               5 (146)           12 (1,295)         
  Other                               5 (131)           7 (827)            
  Unknown                             0 (6)             0 (26)             
  **Node involvement**       14,075                                        $\chi_{2}^{2} = 9.59$, *p* = 0.008
  0 nodes                             56 (1,566)        57 (6,445)         
  1--3 nodes                          27 (771)          25 (2,772)         
  \>3 nodes                           17 (478)          18 (2,043)         
  **Tumor size (mm)**        13,788   10 (17,28)        12 (19,30)         *F*~1.13786~ = 14.02, *p* \< 0.001
  **Tumor size**             9,446                                         $\chi_{2}^{2} = 8.55$, *p* \< 0.014
  0--20 mm                            78 (1,499)        75 (5,675)         
  21--40 mm                           0 (0)             0 (0)              
  41+ mm                              19 (358)          22 (1,627)         
  Unknown                             3 (64)            3 (223)            
  **Grade**                  14,075                                        $\chi_{4}^{2} = 30.19$, *p* \< 0.001
  I                                   13 (375)          11 (1,238)         
  II                                  37 (1,037)        37 (4,122)         
  III                                 43 (1,211)        47 (5,256)         
  IV                                  3 (83)            2 (209)            
  Unknown                             4 (109)           4 (435)            
  **Reconstruction (yes)**   14,075   39 (1,104)        21 (2,318)         $\chi_{1}^{2} = 424.86$, *p* \< 0.001
  **Receptor status**        14,075                                        
  ER: positive                        61 (1,722)        60 (6,734)         $\chi_{1}^{2} = 424.86$, *p* \< 0.001
  ER: negative                        25 (696)          26 (2,909)         
  ER: borderline                      0 (6)             0 (27)             
  ER: unknown                         14 (391)          14 (1,590)         
  PR: positive                        53 (1,482)        51 (5,724)         $\chi_{3}^{2} = 1.94$4, *p* = 0.585
  PR: negative                        32 (907)          34 (3,789)         
  PR: borderline                      0 (11)            1 (62)             
  PR: unknown                         15 (415)          15 (1,685)         

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor.

###### 

Cox proportional hazards model with adjustment for matching and additional covariates

  Variables              Category                              Hazard ratio and 95% confidence limits   *p*-value
  ---------------------- ------------------------------------- ---------------------------------------- -----------
  Mastectomy             Bilateral vs unilateral               0.92 (0.83, 1.02)                        0.109
  Race                   Black vs white                        1.5 (1.35, 1.67)                         \<0.0001
  Other vs white         0.97 (0.83, 1.15)                     0.7512                                   
  Unknown vs white       0.2 (0.03, 1.37)                      0.101                                    
  Radiation              Radiation vs no radiation             0.93 (0.85, 1.02)                        0.1134
  Reconstruction         Reconstruction vs no reconstruction   0.87 (0.79, 0.96)                        0.0074
  Receptor status (ER)   Borderline vs negative                0.47 (0.17, 1.28)                        0.1398
  Positive vs negative   0.76 (0.67, 0.85)                     \<0.0001                                 
  Unknown vs negative    0.88 (0.6, 1.3)                       0.5221                                   
  Receptor status (PR)   Borderline vs negative                1.18 (0.69, 2.02)                        0.5399
  Positive vs negative   0.71 (0.64, 0.8)                      \<0.0001                                 
  Unknown vs negative    0.82 (0.56, 1.19)                     0.2898                                   

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor.
